← All trials
NCT04150965
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2019
- Primary completion
- Oct 1, 2022
- Completion date
- Oct 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 104
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Multiple Myeloma Research ConsortiumLead sponsor
- Harvard UniversityCollaborator
- University of California, San FranciscoOverall official - principal investigator
- Monopar TherapeuticsOverall official - principal investigator
- Harvard UniversityCollaborator
- Emory UniversityCollaborator
- Hackensack University Medical CenterCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
- Antengene CorporationOverall official - principal investigator
- Memorial Sloan-Kettering Cancer CenterCollaborator
- University of MichiganCollaborator
- University of Texas, GalvestonCollaborator
- Wake Forest UniversityCollaborator
- Washington University in St. LouisCollaborator
- Bristol-Myers SquibbCollaborator
- University of California, San FranciscoOfficial
- Monopar TherapeuticsOfficial
- Antengene CorporationOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.